Top

Published in:

01-09-2002 | Review

Interferon-β for treatment of rheumatoid arthritis?

Authors: Judith van Holten, Christine Plater-Zyberk, Paul P Tak

Published in: Arthritis Research & Therapy | Issue 6/2002

Abstract

IFN-β treatment is emerging as a potentially effective form of therapy in various immune-mediated conditions. The present review addresses the possible role of IFN-β in immune-mediated diseases such as multiple sclerosis and rheumatoid arthritis. Several placebo-controlled trials are discussed, as are the available immunological data that are relevant to this field. Review of these data provides evidence that IFN-β has some beneficial therapeutic effect in patients with relapsing-remitting multiple sclerosis and might also have antirheumatic potential. This notion is supported by recent studies showing a critical role for IFN-β in bone homeostasis.

Akbar AN, Lord JM, Salmon M: IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. Immunol Today. 2000, 21: 337-342. 10.1016/S0167-5699(00)01652-2.PubMedCrossRef

De Maeyer E, De Maeyer-Guignard J: Type I interferons. Int Rev Immunol. 1998, 17: 53-73.PubMedCrossRef

Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem. 1998, 67: 227-264. 10.1146/annurev.biochem.67.1.227.PubMedCrossRef

Veys EM, Menkes CJ, Emery P: A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1997, 40: 62-68.PubMedCrossRef

Panitch HS, Hirsch RL, Haley AS, Johnson KP: Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987, 1: 893-895. 10.1016/S0140-6736(87)92863-7.PubMedCrossRef

Chofflon M: Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol. 2000, 7: 369-380. 10.1046/j.1468-1331.2000.00057.x.PubMedCrossRef

Comi G, Colombo B, Martinelli V: Prognosis-modifying therapy in multiple sclerosis. Neurol Sci. 2000, 21 (suppl 2): S893-S899. 10.1007/s100720070033.PubMedCrossRef

Anonymous: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993, 43: 655-661.CrossRef

Anonymous: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998, 352: 1498-1504. 10.1016/S0140-6736(98)03334-0.CrossRef

10.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996, 39: 285-294.PubMedCrossRef

11.

Coclet-Ninin J, Dayer JM, Burger D: Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw. 1997, 8: 345-349.PubMed

12.

Rep MH, Schrijver HM, van Lopik T, Hintzen RQ, Roos MT, Ader HJ, Polman CH, van Lier RA: Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol. 1999, 96: 92-100. 10.1016/S0165-5728(98)00271-9.PubMedCrossRef

13.

Rep MH, Hintzen RQ, Polman CH, van Lier RA: Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996, 67: 111-118.PubMedCrossRef

14.

Tak PP, Hart BA, Kraan MC, Jonker M, Smeets TJ, Breedveld FC: The effects of interferon beta treatment on arthritis. Rheumatology (Oxford). 1999, 38: 362-369. 10.1093/rheumatology/38.4.362.CrossRef

15.

Bielenberg DR, Bucana CD, Sanchez R, Mulliken JB, Folkman J, Fidler IJ: Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol. 1999, 14: 401-408.PubMed

16.

Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol. 1992, 3: 89-96.PubMed

17.

Marchisone C, Benelli R, Albini A, Santi L, Noonan DM: Inhibition of angiogenesis by type I interferons in models of Kaposi's sarcoma. Int J Biol Markers. 1999, 14: 257-262.PubMed

18.

Dvorak HF, Gresser I: Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst. 1989, 81: 497-502.PubMedCrossRef

19.

Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990, 50: 3473-3486.PubMed

20.

Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995, 92: 4562-4566.PubMedPubMedCentralCrossRef

21.

Peacock DJ, Banquerigo ML, Brahn E: Angiogenesis inhibition suppresses collagen arthritis. J Exp Med. 1992, 175: 1135-1138.PubMedCrossRef

22.

Gerlag DM, Borges E, Tak PP, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E, Firestein GS: Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. 2001, 3: 357-361. 10.1186/ar327.PubMedPubMedCentralCrossRef

23.

Oliver SJ, Banquerigo ML, Brahn E: Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM- and a microtubule stabilizer, taxol. Cell Immunol. 1470, 157: 291-299. 10.1006/cimm.1994.1223.CrossRef

24.

Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999, 103: 47-54.PubMedPubMedCentralCrossRef

25.

Diab A, Zhu J, Xiao BG, Mustafa M, Link H: High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J Neuropathol Exp Neurol. 1997, 56: 641-650.PubMedCrossRef

26.

Stinissen P, Raus J, Zhang J: Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol. 1997, 17: 33-75.PubMedCrossRef

27.

Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ: Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999, 53: 1692-1697.PubMedCrossRef

28.

Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Poser S: Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 1994, 44: 1523-1526.PubMedCrossRef

29.

Ozenci V, Kouwenhoven M, Huang YM, Kivisakk P, Link H: Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol. 2000, 120: 147-153. 10.1046/j.1365-2249.2000.01175.x.PubMedPubMedCentralCrossRef

30.

Noronha A, Toscas A, Jensen MA: Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol. 1993, 46: 145-153. 10.1016/0165-5728(93)90244-S.PubMedCrossRef

31.

Yong VW, Chabot S, Stuve O, Williams G: Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998, 51: 682-689.PubMedCrossRef

32.

Cannella B, Cross AH, Raine CS: Adhesion-related molecules in the central nervous system. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest. 1991, 65: 23-31.PubMed

33.

Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF: Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol. 1997, 41: 669-674.PubMedCrossRef

34.

Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.PubMedCrossRef

35.

Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997, 40: 217-225.PubMedCrossRef

36.

Firestein GS: Cytokine networks in rheumatoid arthritis: implications for therapy. Agents Actions Suppl. 1995, 47: 37-51.PubMed

37.

Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994, 344: 1105-1110. 10.1016/S0140-6736(94)90628-9.PubMedCrossRef

38.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfar-lane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1552-1563. 10.1002/1529-0131(199803)41:3<565::AID-ART28>3.3.CO;2-#.PubMedCrossRef

39.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 354: 1932-1939. 10.1016/S0140-6736(99)05246-0.PubMedCrossRef

40.

Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056/NEJM199707173370301.PubMedCrossRef

41.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999, 130: 478-486.PubMedCrossRef

42.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259. 10.1056/NEJM199901283400401.PubMedCrossRef

43.

Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41: 2196-2204. 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U.PubMedCrossRef

44.

Vincenti MP, Clark IM, Brinckerhoff CE: Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?. Arthritis Rheum. 1994, 37: 1115-1126.PubMedCrossRef

45.

Harris ED: Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990, 322: 1277-1289.PubMedCrossRef

46.

Furst DE: Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford). 1999, 38 (suppl 2): 14-18.

47.

Brinckerhoff CE, Auble DT: Regulation of collagenase gene expression in synovial fibroblasts. Ann N Y Acad Sci. 1990, 580: 355-74.PubMedCrossRef

48.

Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW: Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum. 1992, 35: 35-42.PubMedCrossRef

49.

Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE: The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1993, 36: 372-379.PubMedCrossRef

50.

Tak PP, Bresnihan B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000, 43: 2619-2633. 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V.PubMedCrossRef

51.

Carmichael DF, Stricklin GP, Stuart JM: Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. Agents Actions. 1989, 27: 378-379.PubMedCrossRef

52.

Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA: Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. 1994, 37: 629-636.PubMedCrossRef

53.

Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM: Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med. 1995, 122: 81-89.PubMedCrossRef

54.

O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, Eckhoff PJ, Klassen LW, Churchill M, Doud D, Weaver A, Moore GF: Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum. 1999, 42: 1691-1695. 10.1002/1529-0131(199908)42:8<1691::AID-ANR18>3.0.CO;2-S.PubMedCrossRef

55.

Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP: The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum. 2000, 43: 270-274. 10.1002/1529-0131(200002)43:2<270::AID-ANR5>3.0.CO;2-H.PubMedCrossRef

56.

Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y: Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 1999, 42: 90-99. 10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A.PubMedCrossRef

57.

Holten VJ, Sattonet-Roche P, Siegfried C, Graber P, Tak PP, Plater-Zyberk C: Treatment with recombinant interferon beta slows artilage destruction and reduces inflammation in the collagen-induced arthritis model of rheumatoid arthritis [abstract]. Arthritis Rheum. 2000, 43: s231-

58.

Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002, 416: 744-749. 10.1038/416744a.PubMedCrossRef

59.

Alliston T, Derynck R: Medicine: interfering with bone remodelling. Nature. 2002, 416: 686-687. 10.1038/416686a.PubMedCrossRef

60.

Sundel RP, Wallace CA, Zurakowski Boston D: Pilot trial of interferon beta-1a in JRA [abstract]. Arthritis Rheum. 2001, 44: s272-

61.

Alsalameh S, Manger B, Kern P, Kalden J: New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson [letter]. Arthritis Rheum. 1998, 41: 754-10.1002/1529-0131(199804)41:4<754::AID-ART33>3.0.CO;2-K.PubMedCrossRef

62.

Levesque MC, Ward FE, Jeffery DR, Weinberg JB: Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Arthritis Rheum. 1999, 42: 569-573. 10.1002/1529-0131(199904)42:3<569::AID-ANR23>3.0.CO;2-M.PubMedCrossRef

Title: Interferon-β for treatment of rheumatoid arthritis?
Authors: Judith van Holten
Christine Plater-Zyberk
Paul P Tak
Publication date: 01-09-2002
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 6/2002
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar598

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2002

Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study

Paradoxical roles of IFN-γ in models of Th1-mediated autoimmunity

VLA-4-dependent and -independent pathways in cell contact-induced proinflammatory cytokine production by synovial nurse-like cells from rheumatoid arthritis patients

Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome

The role of structural genes in the pathogenesis of osteoarthritic disorders

Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials